Investor News / RNS

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to shareholders were passed. Please click here to read in full....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report for the financial year ended 30th June 2018 and a Circular in relation to its forthcoming Annual General Meeting Please click here to read in full....

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the Company’s history.  Having secured the agreement with Merck KGaA in November 2017, we were able to turn our attention to our pipeline and, leveraging the publicity generated by the Merck deal we converted two large pharmaceutical clients and a biotech client in...

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k and it is expected to complete in this calendar year. Click here to read in full....

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist. Click here to read in full....

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018. Click here to read in full...

Physiomics is pleased to announce that following feedback from clients and shareholders it has today updated its website at http://www.physiomics-plc.com/.  In its recent placing announcement of the 23 May 2018, the Company stated its intention to improve its marketing approach, and the launch of the new site is a small but important step towards executing this goal.  Features of the upgraded site include: Fresher, cleaner...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has completed a placing, conditional only on Admission, to raise £525,000.00 (gross) from the issue of 13,125,000 new ordinary shares of 0.4p each ("Ordinary Shares") at a price of 4.0p per share, through Hybridan LLP (the "Placing"). Application...

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a new UK based biotech client.  The value of the contract is £48k and it is expected to complete in this calendar year. Click here to read in full....

The Company announces that it received notice today that Dr Chassagnole (COO) transferred paper share certificates of 121,522 shares and 265,111 shares to his nominee account ‘Interactive Investor Services Nominees Limited’. Click here to read in full...